Humanigen Inc. (HGEN) Expands its anti-GM-CSF Patent Portfolio
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/3/2026
- S&P 500, Nasdaq eye tepid open as Middle East tensions weigh
- Fed’s Waller open to September rate hold - if disinflation holds up
- Broadcom raises AI chip forecast as Big Tech keeps writing bigger checks
- Nvidia to acquire AI platform Hugging Face in landmark $12.9B deal
- Tesla to unveil Cybercab Texas today, details are few
Humanigen Expands its anti-GM-CSF Patent Portfolio
March 2, 2021 7:00 AM ESTFirst patent issued for the use of lenzilumab to reduce non-GM-CSF cytokines/chemokines that contribute to immunotherapy-related toxicity Second patent issued for the use of lenzilumab to improve the efficacy and durability of immunotherapy
BURLINGAME, Calif.--(BUSINESS WIRE)-- Humanigen, Inc. (Nasdaq: HGEN) (Humanigen) a clinical stage biopharmaceutical company focused on preventing and treating an immune hyper-response called cytokine storm with its lead drug candidate, lenzilumab, today announced the company has been awarded two patents by the United States Patent and Trademark Office (USPTO). These two patents expand... More
